ClinicalTrials.gg
RecruitingNCT06012097Helping HandUpdated Aug 3, 2025

Impact of Gel Aromatherapy on Pain for Patients With De Quervain Disease

A Phase 4 interventional study of Diclofenac gel and Aromatherapy gel in De Quervain Disease, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by University Hospital, Strasbourg, France · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

De Quervain disease is characterized by an adductor pollicis longus and extensor pollicis brevis tendons inflammation as thys pass beneath the extensor retinaculum at the radial styloid. This pathology is recognized as a musculoskeletal disorder of the upper limb triggering functional deficits resulting to possible modifications in the professional activity, sources of absenteeism, thus constituting an economic cost for society. At the etiological level, this pathology also affects young mothers (it's called "mother's wrist" or mommy thumb"), mobile phone users ("textonite", "Blackberryte") or video game players ("Nintendoite").

Currently, the treatment is mainly conservative by splint and anti-inflammatory gel and/or corticosteroid infiltration. Howewer, these therapies have undesirable effects. The interest of this study is therefore to propose another therapy based on aromatherapy gel.

02

Conditions studied

  • De Quervain Disease

Browse trials for

03

In context

De Quervain Disease

31 studies on the registry are indexed under De Quervain Disease; 8 are open to participants now.

This study's planned enrollment of 70 is above the median of 49 across 27 interventional studies indexed under De Quervain Disease.

Browse De Quervain Disease studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patient aged 18 to 75,
  • Patient with unilateral De Quervain's tenosynovitis,
  • Patient cared in the Hand Surgery Department, SOS Mains Emergency Department or Rheumatology Department of Strasbourg University Hospitals,
  • Patient informed of the results of the prior medical examination,
  • signed by the patient,
  • Patient affiliated to a health insurance social protection scheme or beneficiary,
  • For a woman of , negative urine pregnancy test at the inclusion visit and maintenance of effective throughout the study.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding patient,
  • Patient allergic to a component of the gel with essential oils, Dicloflenac®, NSAIDs, or one of the
  • Patient treated with oral non-steroidal anti-inflammatory drugs
  • Patient with ongoing treatment with another ointment at the treatment application site (radial edge of the wrist)
  • Patient with damaged skin, whatever the lesion: oozing dermatosis, eczema, infected lesion, burn or wound,
  • Patient with atopic skin disease,
  • Patient with epilepsy or with a history of epilepsy,
  • Patient with a history of homolateral De Quervain's tenosynovitis, or having already had infiltrations in the 6 months before his inclusion on the ipsilateral side of the pathology,
  • Patient with associated tendinopathies in the elbow or forearm region,
  • Impossibility of giving the patient information (patient in an emergency situation, patient with difficulties of understandin, agitation of the patient),
  • Patient under legal protection, under guardianship or curatorship.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    active comparator

    Diclofenac gel Splint of the thumb and wrist

    Drug: Diclofenac gel

  • Experimental
    Experimental Group

    Aromatherapy Gel Splint of the thumb and wrist

    Drug: Aromatherapy gel

Interventions

  • DrugDiclofenacStudies of DiclofenacDiclofenac pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    using diclofenac as a comparator

  • DrugAromatherapy gel

    using Aromatherapy gel as an experimetnal treatment

06

What researchers measure

Primary outcomes

  1. Measure of pain during the WHAT test

    Visual analogue pain scale (quotation between 0 and 10) during WHAT Test

    Time frame: Day 0

  2. Measure of pain during the WHAT test

    Visual analogue pain scale (quotation between 0 and 10) during WHAT Test

    Time frame: Day 42

  3. Measure of pain during the WHAT test

    Visual analogue pain scale (quotation between 0 and 10) during WHAT Test

    Time frame: Day 84

07

Study locations

1 of 1 sites recruiting
  • Service SOS Main
    Strasbourg, 67000, France
    Recruiting
    • Sybille FACCA · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Apr 2026, 21 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2023
First posted
Aug 25, 2023
StartActual
Jun 4, 2024
Primary completionEst.
Apr 1, 2026
CompletionEst.
Apr 1, 2026
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06012097
Responsible party
Sponsor
First posted
Aug 25, 2023
Start date
Jun 4, 2024
Primary completion
Apr 1, 2026 (estimated)
Completion
Apr 1, 2026 (estimated)
Last update
Aug 3, 2025

Study contacts

Marie SCHWEBEL
Contact
marie.schwebel@chru-strasbourg.fr
03 68 76 53 40

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion